PlainPharmaWatch

CMS Open Payments · Program Year 2024

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation reported $92,749.10 in payments to 45 physicians and teaching hospitals across 45 transactions.

See the rankings → How this is sourced
$92.7K
Total payments
45
Transactions
45
Recipients
+$5.7K
General Payments vs PY2023

Mitsubishi Tanabe Pharma Corporation reported $92,749.10 in payments to 45 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #1203 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $2.1K per recipient across 3 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Mitsubishi Tanabe Pharma Corporation pairs below-median payment volume with a moderately concentrated payment pattern.

#1203
of 1,925 companies
0.0%
of all US industry payments
0.2%
paid to its single top recipient
3
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Mitsubishi Tanabe Pharma Corporation's CMS-reported General Payments increased by $5.7K (+6.5%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: TANABE PHARMA CORPORATIONPY2023: TANABE PHARMA CORPORATIONPY2024: MITSUBISHI TANABE PHARMA CORPORATION. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$87.1KPY2024$92.7K
PY2023
$87,098.21
PY2024
$92,749.10

How Mitsubishi Tanabe Pharma Corporation ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Mitsubishi Tanabe Pharma Corporation's total vs. every reporting company

CMS Open Payments, Program Year 2024

$92,749 38th percentile higher than 38% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). This entry sits in this band. $242,294–$752,621: 270 reporting companies (14%). Above this entry. $752,621–$2,337,813: 263 reporting companies (14%). Above this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Above this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Mitsubishi Tanabe Pharma Corporation

Averaging $2.1K per transaction and $2.1K per recipient, Mitsubishi Tanabe Pharma Corporation's Program Year 2024 total comes to $92,749.10 across 45 transactions and 45 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #1203 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Travel and Lodging" leads the 3-category general-payment breakdown below at $65.6K (70.8% of the company's reported total, 22 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

"Travel and Lodging" leads Mitsubishi Tanabe Pharma Corporation's 3-category general-payment breakdown at $65.6K, 70.8% of the reported total.

How Mitsubishi Tanabe Pharma Corporation divides its payments

How the reported total splits across payment categories

1. Travel and Lodging$65.6K2. Compensation for Services…$26.4K3. Food and Beverage$739.71
Payment Type Amount Transactions
Travel and Lodging $65.6K 22
Compensation for Services Other Than Consulting $26.4K 15
Food and Beverage $739.71 8

Recipient Concentration in General Payments

The five largest recipient relationships account for $82,239.25 (88.7%) of $92,749.10 in this company's General Payments records across 7 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Mitsubishi Tanabe Pharma Corporation

The five named recipients with the highest reported General Payments from this company

Jeffrey Bennett$20.8KMaria Delas Mercedes Perez R…$17.9KDaniel Podolsky$17.5KBruce Sands$15.7KNilay S Sethi$10.5K
  1. 1

    Jeffrey Bennett

    $20,751.83 across 6 reported transactions

  2. 2

    Maria Delas Mercedes Perez Rodriguez

    $17,856.79 across 7 reported transactions

  3. 3

    Daniel Podolsky

    $17,462.90 across 4 reported transactions

  4. 4

    Bruce Sands

    $15,657.49 across 8 reported transactions

  5. 5

    Nilay S Sethi

    $10,510.24 across 6 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $2.1K. Average per recipient: $2.1K.

Total Amount

$92,749.10

Avg per Transaction

$2.1K

Avg per Recipient

$2.1K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Mitsubishi Tanabe Pharma Corporation Share

0.0%

#1203 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Mitsubishi Tanabe Pharma Corporation

Banner Life Sciences, LLC

$92.8K 2,044 recipients

Mid-Atlantic Surgical Systems, LLC

$92.4K 919 recipients

Cardinal Health 110 LLC

$92.3K 166 recipients

Okami Medical, Inc.

$92.0K 263 recipients

OnMark, Inc.

$93.7K 63 recipients

AGEPHA Pharma FZ LLC

$93.7K 510 recipients

Frequently Asked Questions

How much did Mitsubishi Tanabe Pharma Corporation pay to physicians and hospitals in 2024? ▾
Mitsubishi Tanabe Pharma Corporation made $92,749.10 in payments to physicians and hospitals in Program Year 2024, across 45 individual transactions. This represents 0.0% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Mitsubishi Tanabe Pharma Corporation? ▾
45 physicians and teaching hospitals received payments from Mitsubishi Tanabe Pharma Corporation in 2024, averaging $2.1K per recipient.
What types of payments did Mitsubishi Tanabe Pharma Corporation make? ▾
3 categories of general payment make up Mitsubishi Tanabe Pharma Corporation's reported activity, including consulting, meals, travel, and similar types. The largest general-payment category was "Travel and Lodging" at $65.6K, representing 70.8% of the company's reported total.
How does Mitsubishi Tanabe Pharma Corporation rank among pharmaceutical companies? ▾
Out of 1,925 companies in the CMS Open Payments database for 2024, Mitsubishi Tanabe Pharma Corporation ranks #1203 by total payment amount.
What is the average payment size from Mitsubishi Tanabe Pharma Corporation? ▾
Mitsubishi Tanabe Pharma Corporation's 45 transactions to 45 recipients in 2024 averaged $2.1K per transaction.
Where does the payment data for Mitsubishi Tanabe Pharma Corporation come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Mitsubishi Tanabe Pharma Corporation's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.